Upgrades
For Banco Santander SA (NYSE:SAN), Credit Suisse upgraded the previous rating of Neutral to Outperform. Banco Santander earned $0.14 in the fourth quarter, compared to $0.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of $4.38 and a 52-week-low of $2.77. Banco Santander closed at $3.38 at the end of the last trading period.
Goldman Sachs upgraded the previous rating for Comerica Inc (NYSE:CMA) from Sell to Neutral. In the fourth quarter, Comerica showed an EPS of $1.66, compared to $1.49 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.09 and a 52-week-low of $63.07. Comerica closed at $90.43 at the end of the last trading period.
According to Stifel, the prior rating for Centennial Resource Development Inc (NASDAQ:CDEV) was changed from Hold to Buy. For the fourth quarter, Centennial Resource Dev had an EPS of $0.51, compared to year-ago quarter EPS of $0.32. The current stock performance of Centennial Resource Dev shows a 52-week-high of $9.30 and a 52-week-low of $3.69. Moreover, at the end of the last trading period, the closing price was at $8.07.
According to JP Morgan, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Overweight. Comerica earned $1.66 in the fourth quarter, compared to $1.49 in the year-ago quarter. The current stock performance of Comerica shows a 52-week-high of $102.09 and a 52-week-low of $63.07. Moreover, at the end of the last trading period, the closing price was at $90.43.
According to JP Morgan, the prior rating for Vertiv Holdings Co (NYSE:VRT) was changed from Neutral to Overweight. For the fourth quarter, Vertiv Holdings had an EPS of $0.04, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $28.80 and a 52-week-low of $9.59. Vertiv Holdings closed at $14.00 at the end of the last trading period.
According to Credit Suisse, the prior rating for Tellurian Inc (AMEX:TELL) was changed from Neutral to Outperform. Tellurian earned $0.09 in the fourth quarter, compared to $0.00 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.94 and a 52-week-low of $1.62. Tellurian closed at $5.30 at the end of the last trading period.
See all analyst ratings upgrades.
Downgrades
According to JonesTrading, the prior rating for Silverback Therapeutics Inc (NASDAQ:SBTX) was changed from Buy to Hold. In the fourth quarter, Silverback Therapeutics showed an EPS of $0.67, compared to $1.37 from the year-ago quarter. The stock has a 52-week-high of $46.55 and a 52-week-low of $3.36. At the end of the last trading period, Silverback Therapeutics closed at $3.51.
Baird downgraded the previous rating for Walgreens Boots Alliance Inc (NASDAQ:WBA) from Outperform to Neutral. For the second quarter, Walgreens Boots Alliance had an EPS of $1.59, compared to year-ago quarter EPS of $1.26. The stock has a 52-week-high of $57.05 and a 52-week-low of $43.62. At the end of the last trading period, Walgreens Boots Alliance closed at $44.77.
According to Truist Securities, the prior rating for Science Applications International Corp (NYSE:SAIC) was changed from Buy to Hold. In the fourth quarter, Science Applications Intl showed an EPS of $1.50, compared to $1.67 from the year-ago quarter. The stock has a 52-week-high of $96.50 and a 52-week-low of $78.10. At the end of the last trading period, Science Applications Intl closed at $92.17.
For Qorvo Inc (NASDAQ:QRVO), KGI Securities downgraded the previous rating of Outperform to Neutral. For the third quarter, Qorvo had an EPS of $2.98, compared to year-ago quarter EPS of $3.08. The current stock performance of Qorvo shows a 52-week-high of $201.68 and a 52-week-low of $117.03. Moreover, at the end of the last trading period, the closing price was at $124.10.
According to SMBC Nikko, the prior rating for Orchard Therapeutics PLC (NASDAQ:ORTX) was changed from Outperform to Neutral. Orchard Therapeutics earned $0.29 in the fourth quarter, compared to $0.34 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.47 and a 52-week-low of $0.68. Orchard Therapeutics closed at $0.71 at the end of the last trading period.
According to SVB Leerink, the prior rating for Silverback Therapeutics Inc (NASDAQ:SBTX) was changed from Outperform to Market Perform. In the fourth quarter, Silverback Therapeutics showed an EPS of $0.67, compared to $1.37 from the year-ago quarter. The current stock performance of Silverback Therapeutics shows a 52-week-high of $46.55 and a 52-week-low of $3.36. Moreover, at the end of the last trading period, the closing price was at $3.51.
According to Barclays, the prior ...Full story available on Benzinga.com
Benzinga
